



Becoming Australia's leading  
manufacturer & wholesaler of  
novel medicines

ASX:BXN

# Important Notice and Disclaimer



This presentation (Presentation) has been prepared by Bioxyne Limited ABN 97 084 464 193 (Bioxyne or the Company).

The information in this Presentation is of a general background nature, is in summary form and does not purport to be complete. The information in this presentation is subject to change without notice and, subject only to any legal obligations to do so, Bioxyne does not have any obligation to correct or update the contents of this Presentation.

The Presentation contains certain “forward-looking statements”. The words “forecast”, “expect”, “anticipate”, “estimate”, “intend”, “believe”, “guidance”, “should”, “could”, “may”, “will”, “predict”, “plan” and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this Presentation are based on assumptions and contingencies which are subject to change without notice and involve known and unknown risks and certainties and other factors which are beyond the control of Bioxyne, and its directors and management, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. This includes statements about market and industry trends, which are based on interpretations of current market conditions.

Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such statements and any projections and assumptions on which these statements are based. Recipients are cautioned not to place undue reliance on forward-looking statements. Refer to the risk factors section of this Presentation for some of the key known risks. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this Presentation.

The forward-looking statements are based on information available to Bioxyne as at the date of this Presentation. Circumstances may change and the contents of this Presentation may become outdated as a result. Except as required by law or regulation, none of Bioxyne, its representatives or advisers undertakes any obligation to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements.

No party other than Bioxyne has authorised or caused the issue, lodgement, submission, dispatch or provision at the end of this Presentation, or takes any responsibility for, or makes or purports to make any statements, representations or undertakings in this Presentation. To the maximum extent permitted by law, Bioxyne (including its subsidiaries, related bodies corporate, shareholders, affiliates, advisers and agents):

- disclaims all responsibility and liability (including, without limitation, any liability arising from fault, negligence or negligent misstatement) for any loss arising from this Presentation or reliance on anything contained in or omitted from it or otherwise arising in connection with this Presentation;
- disclaims any obligations or undertaking to release any updates or revision to the information in this Presentation to reflect any change in expectations or assumptions; and
- does not make any representation or warranty, express or implied, as to the accuracy, reliability or completeness of the information in this Presentation or the likelihood of fulfilment of any forward-looking statement or any event or results expressed or implied in any forward-looking statement.

## Not An Offer

This Presentation is not a prospectus, product disclosure document or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This Presentation is for information purposes only and should not be considered as, an offer, solicitation, inducement, recommendation or an invitation to acquire securities in Bioxyne or any other financial products, and neither this document nor any of its contents will form the basis of any contract or commitment.

This Presentation may not be distributed to any person in any country outside Australia except to the extent permitted under applicable laws. The release, publication or distribution of this Presentation (including an electronic copy) outside Australia may be restricted by law. If you come into possession of this Presentation, you should observe such restrictions and should seek your own advice on such restrictions. Any non-compliance with these restrictions may contravene applicable securities laws.

## Not Financial Product Advice

This Presentation is not financial product, investment advice or a recommendation to acquire Bioxyne securities and has been prepared without taking into account the objectives, financial situation or needs of individuals. Each recipient of this Presentation should make its own enquiries and investigations regarding all information in this Presentation including, but not limited to, the assumptions, uncertainty and contingencies which may affect future operations of Bioxyne and the impact that different future outcomes may have on Bioxyne. Before making an investment decision prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. Bioxyne is not licensed to provide financial product advice in respect of its securities or any other financial products.

# Investment Highlights



**Strong revenue growth** recording an 81% lift to \$9.66m for FY24, and a run rate of \$16m (at July-2024)



**Holds extensive GMP license** issued by TGA for medicinal cannabis products



**First company licensed by TGA** in Australia to manufacture Psilocybin & MDMA products



**Diversified core of healthcare & wellness revenue streams** from supplements to psychedelic medicines



**Global end-to-end platform** with manufacturing and distribution in UK, Czechia, Japan & Australia



**Growth opportunity** from highly scalable & rapidly replicable pharma GMP manufacturing operations



**Capital light, high-margin business model** focused on building enduring IP & brands

# Executive Summary



Bioxyne is positioned to become Australia’s leading manufacturer & wholesaler of novel medicines in cannabis & psychedelics



**BREATHE LIFE SCIENCES**

B2B manufacturing and wholesaling of raw materials, finished products and APIs



Medicines and consumer health product brands sold in Australia, Europe, UK and Japan

**\$9.66 m**  
Total Revenue for FY24


**~36%**  
FY24 Gross Profit Margin after all selling costs, up from 28% in FY23

**Est. \$28 m**  
2-year supply agreements for THC Gummies

**\$20 m+**  
FY25 Revenue Target, anticipated to be EBITDA positive in H1'25

# Significant Global Distribution & Sales Capabilities

Bioxyne has established a global supply, manufacture and distribution network, now rapidly scaling revenues to service both the B2B & B2C market for its products.



**Biocyte**

# Growth Strategy



# Commercial Milestones to Date



# B2C Business Model

## SOURCING

Certified cultivators & suppliers around the world to deliver only the best APIs & starting materials

## MANUFACTURING

ISO-accredited clean rooms & GMP standards to meet international quality standards across consumer health and pharmaceutical products

## PRODUCT

Globally recognized brands, trusted by businesses and consumers




## DISTRIBUTION

Retail, online and D2C\* distribution across Australia, UK, Europe, Japan



■ Existing Distribution & Sales



<sup>1</sup>AUS (Australia) direct to consumer sales made through pharmacy channels



# B2B Business Model

**SOURCING**

Certified cultivators & suppliers around the world to deliver only the best APIs & starting materials

**CERTIFIED MANUFACTURING**

ISO-accredited clean rooms & GMP certification to meet international PICs quality standards


**PRODUCT**

Globally recognized brands, trusted by consumers




**DISTRIBUTION**

Wholesale to licensed customers, clinics, wholesalers, and other manufacturers.



- Suppliers
- Existing Distribution & Sales



# Growth Plan to Profitability in FY25 Focused on Diversified Revenue Base





## Growth & profitability driven by 3 key segments



Sales and distribution of Dr Watson products (prescription and OTC) in Australia, EU and Japan



High margin manufacture of final dose form cannabis, psilocybin and MDMA



# Near-Term Growth Strategy



		CY24		CY25
B2B	Medicinal cannabis	<ul style="list-style-type: none"> <li>Secure UK licenses for Specials (Cannabis)</li> <li>Import &amp; Launch Dr Watson THC in UK &amp; EU</li> </ul>	<div style="background-color: #00a651; color: white; padding: 10px; text-align: center;"> <b>Deliver Positive Cashflow &amp; EBITDA in H1 FY25</b> </div>	<ul style="list-style-type: none"> <li>Become market leader in AUS for GMP manufacture of “Specials”</li> <li>Manufacture 10,000 kg of THC flower products for Australian patients</li> <li>Ramp up production and supply via authorised prescribers</li> <li>Manufacture 10 million medical cannabis gummies for Australian patients</li> </ul>
	Psilocybin & MDMA	<ul style="list-style-type: none"> <li>Agree psilocybin manufacturing contract with top AUS, NZ, UK &amp; US universities</li> <li>Establish Psychedelic sales and distribution to authorized prescribers and clinics</li> </ul>		<ul style="list-style-type: none"> <li>Extend in-clinic administration of psilocybin &amp; MDMA beyond QLD</li> <li>Continue to supply to trials and research in AUS, UK &amp; US</li> <li>Become Australia’s largest manufacturer of MDMA &amp; Psilocybin, supplying 30%+ of entire market demand</li> </ul>
B2C	Retail & Direct to Consumer	<ul style="list-style-type: none"> <li>Launch Dr Watson prescription products in the UK market with UK clinic and pharmacy partners.</li> <li>Maintain direct to consumer (online &amp; Amazon) growth rate of &gt;100% yoy for Dr Watson brand</li> </ul>		<ul style="list-style-type: none"> <li>Continue to grow direct to consumer, retail, and direct to patient channels of Dr Watson and BLS branded products.</li> </ul>

Long-term strategy is for Bioxyne to successfully register alternative medicines with ARTG for Treatment-Resistant Depression, Post Traumatic Stress Disorder, Cancer Pain



# Financial Overview



# FY24 Financial Performance<sup>1</sup>




Strong performance from provision of psychoactive medicines, supplements and foods made from cannabis, psilocybin & MDMA

**~\$9.66m**  
Total Revenue for FY24

**~\$1.3m**  
Sales for month  
(July-2024)

**~36%**  
FY24 Gross Profit Margin  
after selling costs, up from  
28% in FY23

**\$20.0m+**  
FY25 Target Revenue



<sup>1</sup>Results subject to audit

# Cost Savings Initiatives

Several cost-saving initiatives have been implemented throughout FY24, which will continue to drive financial improvement into FY25

**\$0.30 m**

In cost savings following restructure of UK & EU business units

**\$0.59 m**

In cost savings following discontinuation of MLM and Breathe Compounding Pharmacy businesses


**\$0.65 m**

In one-off costs absorbed for establishment of GMP Facility

**\$1.54 m**


In total cost base improvement to underpin FY25 earnings growth

COST BASE RATIONALISATION



**Strong outlook for FY25 and beyond, following significant cost restructure with anticipated strong growth across core business verticals to deliver positive cash flows and achieve positive EBITDA**

- Bioxyne have implemented a significant cost restructure program and strategic refresh aimed at right-sizing BXN’s cost base and driving concentrated growth in key verticals
- Across the last 12-months, BXN have successfully diversified revenue streams in healthcare/ wellness sector, taking advantage of significant industry tailwinds
- Bioxyne expects to deliver positive cash flow in H12025.



A photograph of a forest floor covered in moss and several mushrooms of varying sizes. The scene is lit with soft, natural light, creating a serene and slightly ethereal atmosphere. The mushrooms are the central focus, with their gills and stems clearly visible. The background shows blurred tree trunks and foliage, suggesting a deep forest setting.

**Biocyte**

**Market  
Opportunity**



# Focused Development of New Treatment Options for Patients Unresponsive to Conventional Therapies



## Substantial opportunity for potential depression therapies from psilocybin and MDMA



**~1BN**

Affected people globally with mental health disorders

**~33%**

Of patients with depression respond inadequately to current treatments

**~16T**

Global economic impact of mental health disorders by 2030

**Up to 12 weeks**

Slow onset of existing/traditional treatments for depression such as SSRIs, NRIs and demonstrably ineffective in long term use (>12 months)

**~2.1M**

Australians affected each year by depression. The Australian Bureau of Statistics (ABS) reported increasing depression rates, particularly in Australian women

**17**


New drugs have been approved by the FDA for psychiatry disorders since 2015, less than 20% relative to oncology

**Bioxyme**

**Appendix**



# Experienced Leadership Team



**Mr. Anthony Ho**

*B. Com (UNSW), CA, FAICD, FCIS, FGIA*  
Non-executive Chairman



**Samuel Watson**

*BSc Finance and Economics*  
Managing Director



**Jason Hine**

*BA Economics and Commerce*  
Executive Director




**Guy Robertson**

*B. Com (Hons.) CA*  
CFO & Company Secretary

- Tony is an experienced company director and is currently a director and chairman of a number of listed ASX companies.
- Tony was executive director of sales and distribution company Arthur Yates & Co Limited, as well as Finance Director/CFO of listed retailers on the ASX – M. S. McLeod Holdings Limited (Downtown Duty Free), Galore Group Limited (Barbeques Galore) and Brazil Limited (Bras N Things, Sanity Music).
- Prior to joining commerce, Tony was a partner of Cox Johnston & Co, Chartered Accountants which has since merged with Ernst & Young.
- Samuel Watson was appointed to the Board on 19 May 2023.
- Sam is the founder and CEO of Breathe Life Sciences (BLS). Since establishing BLS and the Dr Watson Brand in 2018, BLS quickly became a significant player in the health and wellness industry in Europe, UK and Japan. In 2020, BLS entered the Australian market and has grown rapidly into the market leading manufacturer of novel medicines such as MDMA, Psilocybin, and Cannabis.
- Sam is the CEO and founder of Breathe International Ltd, which became Bioxyne's largest shareholder following its all-share acquisition of BLS in 2023.
- Jason was previously the GM Commercial Operations for ECS Botanics Limited, Australia's largest medicinal cannabis and hemp food wellness business.
- The ECS food and wellness business delivers high quality Tasmanian grown/sourced hemp food and wellness products into the Australian grocery sector via the large grocery chains, regional distributors, and a growing bulk supply and B2C channel.
- Jason has been CEO, COO and Managing Director of a number of companies in various industries over a 30-year career.
- Guy is an experienced finance executive, having held the positions of Director, Company Secretary and Chief Financial Officer of both ASX listed and private companies in Australia and Hong Kong.
- Guy held senior roles in the Jardine Matheson Group of Companies including General Manager Finance of Franklins Limited, Chief Operating Officer of Colliers International Asia Pacific and Managing Director (NSW) Jardine Lloyd Thompson.

# Corporate Overview



## CORPORATE SNAPSHOT (17/09/2024)

<b>Shares on Issue</b>	~2,047m
<b>Options &amp; Performance Rights</b>	310 m
<b>Share price</b>	\$0.013
<b>Market capitalisation</b>	\$26.6m
<b>52-week high</b>	\$0.021
<b>52-week low</b>	\$0.004

## MAJOR SHAREHOLDERS

Shareholder	Shares (m)	%
Breathe International Ltd	576,268,527	28.16
Kirkman Trading Ltd	157,805,604	7.71
Ian Edward Owles	132,488,966	6.47
Global Cr Holdings Ltd	114,050,086	5.57
BPMGMT Ltd	79,493,379	3.88
Nam Hoat Chua	63,574,013	3.11
Zonotech Wellness Ltd	57,732,857	2.82
Peng-Hyang Ng	51,500,000	2.52
Paramount Star Investments Limited	36,000,000	1.76



**Bioxyne**

## Contact:

Samuel Watson – Managing Director  
[info@bioxyne.com](mailto:info@bioxyne.com)

James Emonson – Corporate Advisor, Alpine Capital  
[jemonson@alpinecapital.au](mailto:jemonson@alpinecapital.au)